BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 14, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Digital lungs illustration
Respiratory

The TOX-RAGE axis emerges as a potential target for severe pulmonary infections

July 16, 2024
Severe COVID-19 causes a complex lung injury implicating dysregulated immune responses, endothelial dysfunction and coagulopathy, consistent with acute respiratory distress syndrome (ARDS).
Read More

In the clinic for July 9, 2024

July 9, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Cellprothera, Hillevax, Ideaya, Sirnaomics.
Read More

Curevac enters ‘new chapter’ with $1.6B GSK deal, restructuring

July 3, 2024
By Nuala Moran
Curevac AG is casting off the deadweight of its pandemic push to translate its mRNA technology into a marketed COVID-19 vaccine, in a new €1.45 billion (US$1.6 billion) deal in which GSK plc will acquire full rights to infectious disease vaccines the two were co-developing.
Read More
Infection

Pfizer describes new PLpro inhibitors for SARS-CoV-2

July 3, 2024
Pfizer Inc. has identified nonstructural protein 3 (nsp3; PLpro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 (COVID-19) infection.
Read More
Jaeyong Ahn, CEO and president, SK Bioscience

SK Bioscience to acquire Klocke’s CDMO in cross-holding M&A

July 2, 2024
By Marian (YoonJee) Chu
South Korea’s SK Bioscience Co. Ltd. has entered a cross-shareholding acquisition deal with Germany’s Klocke Pharma-Service GmbH to acquire its contract development and manufacturing organization (CDMO), IDT Biologika Corp.
Read More

Regulatory actions for July 2, 2024

July 2, 2024
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Formycon, Humacyte, Idorsia, Longboard, Mesoblast, Sandoz, Springworks, Syncromune, Taurx, Valneva.
Read More

Regulatory actions for July 1, 2024

July 1, 2024
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Abbvie, Apellis, ARS, Iovance, Janssen, Merck, Mirum, Moderna, Pfizer, PTC, Regeneron, Rhythm, Roche, Rocket, Shorla, Soleno.
Read More
Jaeyong Ahn, CEO and president, SK Bioscience

SK Bioscience to acquire Klocke’s CDMO in cross-holding M&A

June 27, 2024
By Marian (YoonJee) Chu
South Korea’s SK Bioscience Co. Ltd. has entered a cross-shareholding acquisition deal with Germany’s Klocke Pharma-Service GmbH to acquire its contract development and manufacturing organization (CDMO), IDT Biologika Corp.
Read More

In the clinic for June 26, 2024

June 26, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ascendis, Astrazeneca, Bioxcel, Douglas, Ethris, Innovent, Lipocine, Merck KGaA, Novo, Soligenix, Tevogen, Wave Life, Werewolf.
Read More

Regulatory actions for June 25, 2024

June 25, 2024
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biogen, Biontech, BMS, Duality, GSK, Mimivax, Novavax, Oncoinvent, Roche, Sellas, Takeda, Valneva.
Read More
Previous 1 2 … 12 13 14 15 16 17 18 19 20 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 14, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing